JUL 22, 2020 7:20 AM PDT

Unmasking the Secrets of the Substantia Nigra to Diagnose Parkinson's

WRITTEN BY: Tara Fernandez

Parkinson’s disease is a devastating condition whereby neurons in a specific region of the brain that controls movement lose functionality or die. This brain region is known as the substantia nigra — which is Latin for "black substance", due to the fact that it contains a high concentration of neuromelanin-containing dopaminergic neurons. As a consequence, those living with Parkinson’s suffer from a suite of debilitating symptoms ranging from shaking, stiffness, and difficulty moving to chronic fatigue and memory difficulties. The early signs of the condition can be incredibly subtle and hard to spot. So, despite being the subject of intense research, there is still neither a definitive diagnostic test nor a cure for Parkinson’s.

Australian Researchers at the University of South Australia are developing a simple neurological imaging tool, which will allow physicians to take a closer look at the specific areas of the brain that are most impacted by Parkinson’s. Brain scans such as PET and SPECT are standard imaging procedures currently used in hospitals. The downside of these imaging tests is, however, the need for patients to be injected with radioactive tracers.

“The significant challenges associated with manufacturing radiotracers and the high cost severely limits patient access to this technology in Australia and elsewhere,” said research lead, Professor Gabrielle Todd. 

“Due to the lack of an accurate and accessible diagnostic test for Parkinson’s disease, this results in a high rate of misdiagnosis.”

To complicate matters further, the interpretation of scans can be subjective, heavily influenced by the expertise level of the physician looking at them as well as the quality of the images. This is no easy feat, especially considering the enormous spectrum of variation within the intricate neuroanatomical features between individuals. It’s no surprise that doctors find it a challenge to make the call of whether the substantia nigra of a suspected Parkinson’s patient can be considered “normal”.

Professor Todd and her team are working on an imaging tool that takes the guesswork out of diagnosing Parkinson’s, especially at the early stages. This platform uses MRI scans as an input (a safe, widely available technique that doesn’t require the administration of radioactive substances) with the goal of it being adopted by hospitals everywhere and not just in specialized departments. The research team is close to establishing an easy-to-use method for objectively measuring and evaluating the substantia nigra from MRI images which are compared to a database of normative data.

“Collectively, we hope to make it easier for radiologists to learn about and interpret abnormal substantia nigra MRI findings and to provide neurologists with more certainty about the patient diagnosis,” said Professor Todd.

 


Sources: University of South Australia, National Institute of Aging.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
SEP 21, 2020
Clinical & Molecular DX
Smart Wearable Patch Signals Trouble Following Traumatic Injury
SEP 21, 2020
Smart Wearable Patch Signals Trouble Following Traumatic Injury
An ambulance pulls up to the site of a car accident, sirens blazing. Paramedics assess the crash victims, looking for si ...
OCT 29, 2020
Clinical & Molecular DX
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
OCT 29, 2020
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
 
NOV 27, 2020
Clinical & Molecular DX
From Months to Hours - Digital Tools Accelerate Dermatological Diagnoses
NOV 27, 2020
From Months to Hours - Digital Tools Accelerate Dermatological Diagnoses
Getting that nasty rash tested isn’t always a straightforward process. Dermatologists have notoriously long waitli ...
DEC 26, 2020
Clinical & Molecular DX
Navigating the Genomic Landscape of Cancer in Asians
DEC 26, 2020
Navigating the Genomic Landscape of Cancer in Asians
Precision medicine — a clinical paradigm that tailors treatments specifically to patients based on their genetic a ...
DEC 29, 2020
Cardiology
Does Physical Activity Help Reduce the Risk of Aneurysms?
DEC 29, 2020
Does Physical Activity Help Reduce the Risk of Aneurysms?
An active lifestyle is a proven way to prevent many types of cardiovascular diseases. The increased blood flow can preve ...
DEC 30, 2020
Neuroscience
Brain Imaging Predicts Risk of PTSD
DEC 30, 2020
Brain Imaging Predicts Risk of PTSD
Until now, why posttraumatic stress disorder (PTSD) develops in some and not others following a physical and/ or psychol ...
Loading Comments...